vs

Side-by-side financial comparison of Caesarstone Ltd. (CSTE) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

Caesarstone Ltd. is the larger business by last-quarter revenue ($94.4M vs $85.1M, roughly 1.1× 4D Molecular Therapeutics, Inc.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs -93.1%, a 115.9% gap on every dollar of revenue. 4D Molecular Therapeutics, Inc. produced more free cash flow last quarter ($28.5M vs $-47.1M). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -57.8%).

Caesarstone Ltd., is a publicly traded company that engages in the production and marketing of quartz, porcelain, mineral and advanced fusion surfaces used for kitchen countertops, vanity tops, flooring, wall cladding and general interior design. The company was founded in 1987 and is traded on the NASDAQ in New York (CSTE). Headquarters are located in Kibbutz Sdot Yam in Israel. Production facilities are in Israel and India with third party manufactured product sourced from factories in the ...

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

CSTE vs FDMT — Head-to-Head

Bigger by revenue
CSTE
CSTE
1.1× larger
CSTE
$94.4M
$85.1M
FDMT
Higher net margin
FDMT
FDMT
115.9% more per $
FDMT
22.8%
-93.1%
CSTE
More free cash flow
FDMT
FDMT
$75.5M more FCF
FDMT
$28.5M
$-47.1M
CSTE
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-57.8%
CSTE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CSTE
CSTE
FDMT
FDMT
Revenue
$94.4M
$85.1M
Net Profit
$-87.9M
$19.4M
Gross Margin
15.5%
Operating Margin
-87.2%
17.3%
Net Margin
-93.1%
22.8%
Revenue YoY
8508900.0%
Net Profit YoY
139.1%
EPS (diluted)
$-2.55
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CSTE
CSTE
FDMT
FDMT
Q4 25
$94.4M
$85.1M
Q3 25
$345.4M
$90.0K
Q2 25
$237.7M
$15.0K
Q1 25
$14.0K
Q4 24
$1.0K
Q3 24
$436.7M
$3.0K
Q2 24
$294.3M
$5.0K
Q1 24
$150.6M
$28.0K
Net Profit
CSTE
CSTE
FDMT
FDMT
Q4 25
$-87.9M
$19.4M
Q3 25
$-18.5M
$-56.9M
Q2 25
$-14.3M
$-54.7M
Q1 25
$-48.0M
Q4 24
Q3 24
$-57.4M
$-43.8M
Q2 24
$-56.6M
$-35.0M
Q1 24
$-3.9M
$-32.4M
Gross Margin
CSTE
CSTE
FDMT
FDMT
Q4 25
15.5%
Q3 25
22.5%
Q2 25
23.7%
Q1 25
Q4 24
Q3 24
15.7%
Q2 24
14.1%
Q1 24
19.7%
Operating Margin
CSTE
CSTE
FDMT
FDMT
Q4 25
-87.2%
17.3%
Q3 25
-5.5%
-67983.3%
Q2 25
-6.2%
-396373.3%
Q1 25
-383007.1%
Q4 24
Q3 24
-12.6%
-1704400.0%
Q2 24
-18.0%
-849120.0%
Q1 24
-3.9%
-136200.0%
Net Margin
CSTE
CSTE
FDMT
FDMT
Q4 25
-93.1%
22.8%
Q3 25
-5.4%
-63195.6%
Q2 25
-6.0%
-364386.7%
Q1 25
-342657.1%
Q4 24
Q3 24
-13.1%
-1461433.3%
Q2 24
-19.2%
-699060.0%
Q1 24
-2.6%
-115717.9%
EPS (diluted)
CSTE
CSTE
FDMT
FDMT
Q4 25
$-2.55
$0.43
Q3 25
$-0.54
$-1.01
Q2 25
$-0.41
$-0.98
Q1 25
$-0.86
Q4 24
Q3 24
$-1.67
$-0.79
Q2 24
$-1.64
$-0.63
Q1 24
$-0.11
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CSTE
CSTE
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$58.4M
$402.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$139.2M
$505.7M
Total Assets
$398.4M
$566.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CSTE
CSTE
FDMT
FDMT
Q4 25
$58.4M
$402.7M
Q3 25
$305.1M
Q2 25
$293.2M
Q1 25
$321.4M
Q4 24
$424.9M
Q3 24
$501.9M
Q2 24
$541.9M
Q1 24
$525.9M
Total Debt
CSTE
CSTE
FDMT
FDMT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$-12.6M
Stockholders' Equity
CSTE
CSTE
FDMT
FDMT
Q4 25
$139.2M
$505.7M
Q3 25
$271.6M
$369.0M
Q2 25
$271.6M
$420.9M
Q1 25
$469.7M
Q4 24
$510.6M
Q3 24
$315.1M
$552.9M
Q2 24
$315.1M
$588.3M
Q1 24
$315.1M
$600.6M
Total Assets
CSTE
CSTE
FDMT
FDMT
Q4 25
$398.4M
$566.7M
Q3 25
$549.0M
$424.0M
Q2 25
$549.0M
$473.6M
Q1 25
$515.7M
Q4 24
$560.4M
Q3 24
$579.9M
$604.0M
Q2 24
$579.9M
$620.1M
Q1 24
$579.9M
$629.9M
Debt / Equity
CSTE
CSTE
FDMT
FDMT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CSTE
CSTE
FDMT
FDMT
Operating Cash FlowLast quarter
$-38.0M
$28.6M
Free Cash FlowOCF − Capex
$-47.1M
$28.5M
FCF MarginFCF / Revenue
-49.8%
33.5%
Capex IntensityCapex / Revenue
9.6%
0.1%
Cash ConversionOCF / Net Profit
1.47×
TTM Free Cash FlowTrailing 4 quarters
$38.6M
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CSTE
CSTE
FDMT
FDMT
Q4 25
$-38.0M
$28.6M
Q3 25
$35.0M
$-46.5M
Q2 25
$18.7M
$-43.4M
Q1 25
$-47.8M
Q4 24
$-134.6M
Q3 24
$53.3M
$-29.4M
Q2 24
$25.1M
$-30.2M
Q1 24
$7.9M
$-29.1M
Free Cash Flow
CSTE
CSTE
FDMT
FDMT
Q4 25
$-47.1M
$28.5M
Q3 25
$26.7M
$-46.6M
Q2 25
$14.3M
$-43.4M
Q1 25
$-48.4M
Q4 24
$-138.4M
Q3 24
$44.6M
$-31.2M
Q2 24
$20.7M
$-30.6M
Q1 24
$5.0M
$-29.8M
FCF Margin
CSTE
CSTE
FDMT
FDMT
Q4 25
-49.8%
33.5%
Q3 25
7.7%
-51765.6%
Q2 25
6.0%
-289620.0%
Q1 25
-345635.7%
Q4 24
-13837100.0%
Q3 24
10.2%
-1038966.7%
Q2 24
7.0%
-611840.0%
Q1 24
3.3%
-106421.4%
Capex Intensity
CSTE
CSTE
FDMT
FDMT
Q4 25
9.6%
0.1%
Q3 25
2.4%
101.1%
Q2 25
1.8%
440.0%
Q1 25
4507.1%
Q4 24
378600.0%
Q3 24
2.0%
59266.7%
Q2 24
1.5%
6980.0%
Q1 24
1.9%
2535.7%
Cash Conversion
CSTE
CSTE
FDMT
FDMT
Q4 25
1.47×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CSTE
CSTE

America's$53.0M56%
USA$41.4M44%

FDMT
FDMT

Segment breakdown not available.

Related Comparisons